Altimmune (ALT) Income from Continuing Operations (2010 - 2026)
Altimmune (ALT) reported Income from Continuing Operations of 22563000.0 for Q1 2026, down 15.26% year-over-year from 26627523.06 in Q1 2025, and down 138.98% quarter-over-quarter from 57890000.0 in Q4 2025.
Altimmune (ALT) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Altimmune (ALT) has 17 years of Income from Continuing Operations data on file, last reported at 22563000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 22563000.0, down 15.26% year-over-year; the trailing twelve-month figure through Mar 2026 was 5833000.0 (up 93.54% YoY), and the FY2025 annual result was 2845000.0, up 97.01% from the prior year.
- Income from Continuing Operations fell to 22563000.0 in Q1 2026 per ALT's latest filing, from 57890000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 57890000.0 in Q4 2025 and troughed at 24640000.0 in Q2 2024.
- A 5-year average of 11670235.29 and a median of 20132000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations surged 1049.28% in 2022, then tumbled 160.71% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 51090000.0 in 2022, then slumped by 117.4% to 8891000.0 in 2023, then sank by 160.71% to 23180000.0 in 2024, then jumped by 349.74% to 57890000.0 in 2025, then slumped by 138.98% to 22563000.0 in 2026.
- Business Quant data shows ALT's Income from Continuing Operations at 22563000.0 in Q1 2026, 57890000.0 in Q4 2025, and 19014000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Altimmune | 336.67 Mn | 336.67 Mn | - | -22.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.56 Mn |
| Dec 31, 2025 | 57.89 Mn |
| Sep 30, 2025 | -19.01 Mn |
| Jun 30, 2025 | -22.15 Mn |
| Mar 31, 2025 | -19.58 Mn |
| Dec 31, 2024 | -23.18 Mn |
| Sep 30, 2024 | -22.85 Mn |
| Jun 30, 2024 | -24.64 Mn |
| Mar 31, 2024 | -24.39 Mn |
| Dec 31, 2023 | -8.89 Mn |
| Sep 30, 2023 | -20.67 Mn |
| Jun 30, 2023 | -16.17 Mn |
| Mar 31, 2023 | -20.09 Mn |
| Dec 31, 2022 | 51.09 Mn |
| Sep 30, 2022 | -23.52 Mn |
| Jun 30, 2022 | -20.13 Mn |
| Mar 31, 2022 | -19.54 Mn |
| Dec 31, 2021 | -5.38 Mn |
| Sep 30, 2021 | -33.51 Mn |
| Jun 30, 2021 | -24.83 Mn |